Full Text View
Tabular View
No Study Results Posted
Related Studies
Evaluating the Ability of Zoledronic Acid to Reduce the Rate of Subsequent Osteoporotic Fractures After a Hip Fracture
This study has been completed.
Study NCT00046254   Information provided by Novartis
First Received: September 24, 2002   Last Updated: September 24, 2007   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Osteoporosis
Hip Fracture
Additional conditions recognized in this trial
Fractures, Bone
Hip Fractures
More general conditions related to this trial
Bone Diseases
Bone Diseases, Metabolic
Disorders of Environmental Origin
Femoral Fractures
Hip Injuries
Leg Injuries
Musculoskeletal Diseases
Wounds and Injuries
Interventions listed in this trial
Zoledronic Acid
Additional drug interventions recognized in this trial
Diphosphonates
More general drug interventions related to this trial
Bone Density Conservation Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
Novartis


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services